These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22196450)

  • 1. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.
    Schaeffeler E; Hellerbrand C; Nies AT; Winter S; Kruck S; Hofmann U; van der Kuip H; Zanger UM; Koepsell H; Schwab M
    Genome Med; 2011 Dec; 3(12):82. PubMed ID: 22196450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.
    Heise M; Lautem A; Knapstein J; Schattenberg JM; Hoppe-Lotichius M; Foltys D; Weiler N; Zimmermann A; Schad A; Gründemann D; Otto G; Galle PR; Schuchmann M; Zimmermann T
    BMC Cancer; 2012 Mar; 12():109. PubMed ID: 22439694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.
    Lautem A; Heise M; Gräsel A; Hoppe-Lotichius M; Weiler N; Foltys D; Knapstein J; Schattenberg JM; Schad A; Zimmermann A; Otto G; Lang H; Galle PR; Schuchmann M; Zimmermann T
    Int J Oncol; 2013 Apr; 42(4):1297-304. PubMed ID: 23440379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
    Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
    Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
    Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
    Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
    Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low expression of SLC22A1 is associated with a poor prognosis of hepatocellular carcinoma: analysis of 303 patients].
    Wang ST; Shen SL; Hua YP; Chen B; Kuang M; Li SQ; He Q; Peng BG
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Oct; 35(10):1417-21. PubMed ID: 26547334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.
    Vollmar J; Kim YO; Marquardt JU; Becker D; Galle PR; Schuppan D; Zimmermann T
    Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G195-G202. PubMed ID: 31241979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
    Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional inhibition of Oct leads to HNF4α upregulation.
    Vollmar J; Kim YO; Marquardt JU; Galle PR; Schuppan D; Zimmermann T
    Exp Ther Med; 2021 Apr; 21(4):349. PubMed ID: 33732322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
    García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C
    Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Organic Cation Transporters (OCT-SLC22A) on Differential Diagnosis of Intrahepatic Lesions.
    Visentin M; van Rosmalen BV; Hiller C; Bieze M; Hofstetter L; Verheij J; Kullak-Ublick GA; Koepsell H; Phoa SS; Tamai I; Bennink RJ; van Gulik TM; Stieger B
    Drug Metab Dispos; 2017 Feb; 45(2):166-173. PubMed ID: 27903597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic imprinting of the IGF2R/AIR locus is conserved between bovines and mice.
    Liu X; Huo H; Jin L; Dong Y; Li D; Zhang C; Li S
    Theriogenology; 2022 Mar; 180():121-129. PubMed ID: 34971973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical significance of organic cation transporter family in glioblastoma multiforme.
    Lian Q; Xiao S; Wang Y; Wang H; Xie D
    Ir J Med Sci; 2022 Jun; 191(3):1115-1121. PubMed ID: 34080124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.
    Chen M; Neul C; Schaeffeler E; Frisch F; Winter S; Schwab M; Koepsell H; Hu S; Laufer S; Baker SD; Sparreboom A; Nies AT
    Clin Pharmacol Ther; 2020 Jan; 107(1):227-237. PubMed ID: 31350763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and Epigenetic Regulation of Organic Cation Transporters.
    Kölz C; Schaeffeler E; Schwab M; Nies AT
    Handb Exp Pharmacol; 2021; 266():81-100. PubMed ID: 33674913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.
    Sala-Rabanal M; Li DC; Dake GR; Kurata HT; Inyushin M; Skatchkov SN; Nichols CG
    Mol Pharm; 2013 Apr; 10(4):1450-8. PubMed ID: 23458604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
    Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
    Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.
    Vollmar J; Lautem A; Closs E; Schuppan D; Kim YO; Grimm D; Marquardt JU; Fuchs P; Straub BK; Schad A; Gründemann D; Schattenberg JM; Gehrke N; Wörns MA; Baumgart J; Galle PR; Zimmermann T
    Oncotarget; 2017 Dec; 8(70):115667-115680. PubMed ID: 29383190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.